Table 2.
Ongoing clinical trials investigating the use of tyrosine-kinase inhibitors for hepatocellular carcinoma treatment.
| Molecule Name | Study Title | Status | Drugs | Phase | NCT Number |
|---|---|---|---|---|---|
| Sorafenib | YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | Recruiting | Drug: YIV-906 plus Sorafenib Drug: Placebo plus Sorafenib |
II | NCT04000737 |
| Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC | Recruiting | Drug: Sorafenib Procedure: Transarterial chemoembolization |
III | NCT04143191 | |
| HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | Recruiting | Procedure: Hepatic arterial infusion chemotherapy Drug: Toripalimab Drug: Sorafenib |
II | NCT04135690 | |
| SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | Recruiting | Radiation: SBRT+TACE+Sorafenib Drug: Sorafenib |
III | NCT04387695 | |
| Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation | Recruiting | Drug: Arsenical Drug: Sorafenib |
II | NCT04232722 | |
| Regorafenib | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | Recruiting | Drug: Regorafenib Drug: Nivolumab |
I and II | NCT04170556 |
| Lenvantinib | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma | Recruiting | Drug: Lenvima 4 mg Oral Capsule | II | NCT04227808 |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma | Recruiting | Drug: Lenvatinib Drug: Nivolumab |
II | NCT03841201 | |
| Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | Recruiting | Drug: Lenvatinib Drug: Tislelizumab |
II | NCT04401800 | |
| A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma | Recruiting | Drug: CS1003 plus Lenvatinib Drug: CS1003 Placebo plus Lenvatinib |
III | NCT04194775 | |
| HAIC Plus Lenvatinib and Toripalimab for Advanced HCC | Recruiting | Procedure: Hepatic arterial infusion chemotherapy Drug: Lenvatinib Drug: Toripalimab |
II | NCT04044313 | |
| Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis | Recruiting | Procedure: Systemic chemotherapy Drug: Lenvatinib Drug: Toripalimab |
II | NCT04170179 | |
| PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC | Recruiting | Combination Product: PD-1 mAb combined with TACE and Lenvatinib | II | NCT04273100 | |
| TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC | Recruiting | Procedure: TACE Drug: Lenvatinib |
III | NCT03905967 | |
| Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | Recruiting | Drug: Lenvatinib | II | NCT04241523 | |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | Recruiting | Drug: Lenvatinib Biological: Pembrolizumab Drug: Oral Placebo Drug: IV Placebo Procedure: TACE |
III | NCT04246177 | |
| A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | Recruiting | Drug: E7386 Drug: Lenvatinib |
I | NCT04008797 | |
| Cabozantinib | Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) | Recruiting | Drug: Cabozantinib group Other: ECG |
IV | NCT03963206 |
| Brivanib | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | Recruiting | Drug: MGD013 monotherapy Drug: MGD013 in combination with Brivanib Alaninate |
I and II | NCT04212221 |
| Apatinib | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma | Recruiting | Drug: Apatinib Combined With SHR-1210 Injection | II | NCT04297202 |
| SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma | Recruiting | Drug: SHR-1210 Drug: Apatinib |
II | NCT04014101 | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | Recruiting | Combination Product: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab | II | NCT04191889 | |
| Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | Recruiting | Drug: Camrelizumab plus Apatinib | I and II | NCT04035876 | |
| The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | Recruiting | Drug: Apatinib Mesylate Drug: SHR-1210 |
II | NCT04204577 | |
| RFA Plus Carrizumab and Apatinib vs Carrizumab and Apatinib Alone for HCC | Recruiting | Combination Product: radiofrequency ablation plus Carrizumab and Apatinib Combination Product: Carrizumab and Apatinib |
II | NCT04150744 | |
| A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC | Recruiting | Drug: SHR-1210 Drug: Apatinib Drug: Sorafenib |
III | NCT03764293 |
Summarized are the ongoing clinical trials found on ClinicalTrials.gov by searching the keywords “hepatocellular carcinoma” and “each small molecule name”. The research has been done adding the following filters: “Active, not recruiting”; “Recruiting”; “Study starts from 06/01/2019”. Trials with the principal small molecule used only as a comparative drug are not included.